Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

16    Mylan    $5.6B    up 16.7%
Global revenue: $6.1B (19th); up 10.9%

R&D spend: $282M (20th), up 4.6%; 4.8% of rev.

Top brands: Fentanyl ($472M), bupropion XL ($336M), omeprazole Rx ($242M), EpiPen ($226M)

Planned launches: Generic versions of Advair Diskus (resp.)

Promotional spend: $2M (20th); 0.04% of rev.

Patent expirations: N/A

Five years ago, the Pittsburgh generics giant cobbled together an empire through its acquisitions of Dey Pharma, Matrix Laboratories and the Merck KGaA generics business, going from being the No. 3 player in US generics to No. 3 worldwide. Now Mylan is looking to expand in markets where generics are underutilized, including much of Europe, the Middle East and Asia (half the company's revenues come from generics-happy North America), while increasing the number of products it markets from 4,700 to 6,700 by 2015 and pushing into generic biologics. The firm faces some generic erosion of its own, though, as Sanofi and Intelliject will launch a competitor to its lucrative EpiPen Auto-Injector franchise in November.

Back to first page

Page 16 of 21
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?